TL;DR
Epstein-Barr virus (EBV) nuclear antigen leader protein (LP) plays a crucial role in transforming B lymphocytes into lymphoblastoid cell lines (LCLs) by localizing to gene promoters and working alongside cellular transcription factors. This study reveals that LP, often in conjunction with EBNA2 (E2), actively removes repressive complexes from DNA, thereby facilitating gene activation and promoting cell growth and survival.
What Problem Does This Paper Address?
Epstein-Barr virus (EBV) is known to infect B lymphocytes and drive their transformation into lymphoblastoid cell lines (LCLs), a process critical for the virus's life cycle and implicated in certain cancers. Two key viral proteins, EBNA leader protein (LP) and EBNA2 (E2), are essential for this transformation. While E2's role in activating transcription from distal enhancers is somewhat understood, the precise molecular mechanisms by which LP and E2 cooperate to orchestrate this cellular transformation, particularly LP's contribution, remained largely unclear. This paper aims to elucidate LP's genome-wide binding patterns, its association with cellular transcription factors, and its role in gene activation, especially in concert with E2.
Methods
The researchers employed a genome-wide approach using Chromatin Immunoprecipitation followed by sequencing (ChIP-seq) to map the binding sites of EBV's LP and EBNA2 (E2) across the genome of LCLs. They analyzed these ChIP-seq datasets using the HOMER software suite for motif discovery and peak annotation. To understand the functional context of these binding sites, they integrated publicly available ENCODE ChIP-seq data for various cellular transcription factors (TFs) and histone modifications. They also utilized RNA-sequencing (RNA-seq) data to correlate LP/E2 binding with gene expression levels. K-means clustering was used to categorize LP binding sites based on their associated TF profiles, allowing for a deeper analysis of functional heterogeneity.
Datasets
The study utilized publicly available ENCODE ChIP-seq datasets for various human B-cell transcription factors and histone modifications in LCLs. They also used their own generated ChIP-seq data for EBV LP and EBNA2 (E2) in LCLs. RNA-seq data from LCLs was also used to assess gene expression. No new benchmarks were introduced; rather, existing datasets were integrated and analyzed.
Key Insights and Ideas
- LP is a Promoter-Centric Regulator: Unlike E2, which is known to act at enhancers, LP shows a strong preference for localizing to gene promoters, often within 2 kb of a transcriptional start site.
- LP Collaborates with a Broad Spectrum of Cellular TFs: LP binding sites are significantly enriched for a wide array of B-cell transcription factors crucial for lymphocyte development and function, including YY1, SP1, PAX5, BATF, IRF4, ETS1, RAD21, PU.1, CTCF, RBPJ, ZNF143, SMC3, NFκB, and EBF.
- LP and E2 Cooperate Synergistically: A substantial portion of LP sites (29%) overlap with E2 sites (LP/E2 sites). These co-occupied sites exhibit a unique profile, being more highly occupied by cellular TFs and showing higher transcriptional activity than sites occupied by LP or E2 alone.
- LP's Role in Repressor Depletion: LP is implicated in removing repressive complexes (like NCOR and RBPJ) from DNA, a key step in activating transcription. This derepression activity is particularly evident at sites co-occupied with CTCF, a known insulator and DNA looping factor.
- LP and E2 Target Key Genes for LCL Growth: LP is found at promoters and enhancers of genes critical for LCL proliferation and survival, including those regulated by MYC, such as ccnd2, igf2r, and bcl2.
Key Results
- Genome-wide Binding: LP was identified at 19,224 sites, with approximately 50% located within ±2 kb of a transcriptional start site. E2 was found at 19,845 sites.
- TF Enrichment: LP sites showed significant enrichment for numerous B-cell TFs. LP/E2 sites were generally more highly occupied by these TFs compared to LP-only or E2-only sites, with the exception of EBF, which was more enriched at E2 sites.
- Epigenetic Marks: LP sites were strongly associated with active promoter marks (H3K4me3, H3K27ac, H2Az, H3K9ac, RNAPII, P300). LP/E2 sites showed even higher levels of these marks, indicating heightened transcriptional activity. E2 sites, more associated with enhancers, showed higher H3K4me1 marks.
- Gene Expression: Genes associated with LP, E2, or LP/E2 binding were significantly more highly expressed than random control genes. LP/E2-annotated genes were more highly expressed than E2-annotated genes. Genes with co-occupied CTCF and LP sites were significantly more highly expressed than those with CTCF sites alone.
- LP Site Clustering: K-means clustering revealed distinct patterns of TF association at LP sites, with some clusters enriched for developmental TFs and others for DNA looping factors, suggesting functional heterogeneity.
Limitations and Future Work
The authors acknowledge that while the study highlights LP's role in promoter localization and repressor removal, and E2's role at enhancers, the precise mechanisms by which these two proteins cooperate to activate transcription remain complex and require further deconstruction. They suggest that future work could involve using shRNAs to individually knock down LP, E2, and their associated cell TFs to better understand their specific contributions to proliferation and survival pathways. The study also points to the need for further investigation into how LP and E2, through their interactions with TFs and DNA looping factors, orchestrate the complex transcriptional programs necessary for LCL growth and survival.
Summary updated